story of the week
Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma
N. Engl. J. Med 2019 Aug 22;381(8)727-738, A Chari, DT Vogl, M Gavriatopoulou, AK Nooka, AJ Yee, CA Huff, P Moreau, D Dingli, C Cole, S Lonial, M Dimopoulos, AK Stewart, J Richter, R Vij, S Tuchman, MS Raab, KC Weisel, M Delforge, RF Cornell, D Kaminetzky, JE Hoffman, LJ Costa, TL Parker, M Levy, M Schreder, N Meuleman, L Frenzel, M Mohty, S Choquet, G Schiller, RL Comenzo, M Engelhardt, T Illmer, P Vlummens, C Doyen, T Facon, L Karlin, A Perrot, K Podar, MG Kauffman, S Shacham, L Li, S Tang, C Picklesimer, JR Saint-Martin, M Crochiere, H Chang, S Parekh, Y Landesman, J Shah, PG Richardson, S JagannathFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.